Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Capital Expenditures (2020 - 2025)

Tarsus Pharmaceuticals has reported Capital Expenditures over the past 6 years, most recently at -$2.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$2.0 million for Q4 2025, down 2836.11% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 2.3% YoY), and the annual figure for FY2025 was $1.5 million, down 2.3%.
  • Capital Expenditures for Q4 2025 was -$2.0 million at Tarsus Pharmaceuticals, down from $3.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for TARS hit a ceiling of $3.2 million in Q3 2025 and a floor of -$2.0 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $216500.0 (2021), compared with a mean of $289277.8.
  • Peak annual rise in Capital Expenditures hit 1019.5% in 2025, while the deepest fall reached 2836.11% in 2025.
  • Tarsus Pharmaceuticals' Capital Expenditures stood at $274000.0 in 2021, then plummeted by 108.39% to -$23000.0 in 2022, then surged by 1730.43% to $375000.0 in 2023, then tumbled by 80.8% to $72000.0 in 2024, then crashed by 2836.11% to -$2.0 million in 2025.
  • The last three reported values for Capital Expenditures were -$2.0 million (Q4 2025), $3.2 million (Q3 2025), and $305000.0 (Q2 2025) per Business Quant data.